Epstein Secrets

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

d foreign actors are creating a "perception hack," meaning they want the "perception that they're inside the system, and sow distrust," according to David Sanger. Clapper said his office's "first key judgment in 2016" was that "the initial objective was to sow doubt, discord, and discontent." Clapper added t

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

foreign actors are creating a "perception hack," meaning they want the "perception that they're inside the system, and sow distrust," according to David Sanger. Clapper said his office's "first key judgment in 2016" was that "the initial objective was to sow doubt, discord, and discontent." Clapper added th

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

d foreign actors are creating a "perception hack," meaning they want the "perception that they're inside the system, and sow distrust," according to David Sanger. Clapper said his office's "first key judgment in 2016" was that "the initial objective was to sow doubt, discord, and discontent." Clapper added t